Related content

Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol–cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study

By Elter Koray   Imir Gonca   Durmusoglu Fatih  

Human Reproduction, Vol. 17, Iss. 7, 2002-07 ,pp. : 1729-1737

Oxford University Press

Access to resources Recommend Favorite

Effects of ethinyl estradiol-cyproterone acetate treatment on metabolic syndrome, fat distribution and carotid intima media thickness in polycystic ovary syndrome

By Karabulut Aysun   Demirlenk Semra   ŞŞevket Osman  

Gynecological Endocrinology, Vol. 28, Iss. 4, 2012-04 ,pp. : 245-248

Informa Healthcare

Access to resources Recommend Favorite

Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance

By Lemay A.   Dodin S.   Turcot L.   Déchêne F.   Forest J-C.  

Human Reproduction, Vol. 21, Iss. 1, 2006-01 ,pp. : 121-128

Oxford University Press

Access to resources Recommend Favorite

Urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women with polycystic ovary syndrome: the effect of ethinyl estradiol-cyproterone acetate treatment

By Luboshitzky R.   Shen-Orr Z.   Herer P.   Nave R.  

Gynecological Endocrinology, Vol. 17, Iss. 6, 2003-12 ,pp. : 441-447

Informa Healthcare

Access to resources Recommend Favorite

Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin

By Luque-Ramrez Manuel   lvarez-Blasco Francisco   Uriol Rivera Miguel Giovanni   Escobar-Morreale Hctor F.  

Human Reproduction, Vol. 23, Iss. 7, 2008-07 ,pp. : 1594-1601

Oxford University Press

Access to resources Recommend Favorite